Farname Inc. in collaboration with Iranian Society of Gynecology Oncology

Document Type : Original Research Article

Authors

Shahid AkbarAbadi Clinical Research Development unit (SHACRDU), School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran

Abstract

Background & Objective: Clomiphene resistance is an important problem among women with Polycystic Ovarian Disease (PCOD) suffering from infertility. Recognition of the causes would result in better prognosis in these patients. This study was performed to determine different PCOD phenotypes and their effects on clomiphene resistance in infertile women.
Materials & Methods: In this descriptive-comparative cross-sectional study, 200 consecutive PCOD women with infertility taking clomiphene who were reffered to Akbarabadi hospital in 2017 and 2018 were enrolled. Different PCOD phenotypes and their effects on clomiphene resistance among these women were assessed.
Results: The results showed that A, B, C, and D phenotypes were observed in 79 (39.5%), 13 (6.5%), 51 (25.5%), and 57 (28.5%) patients, respectively. Sixty-one patients (30.5%) had resistance. Despite no significant difference between phenotypes (P=0.064), the most common PCOD phenotype was A (HA+OA+PCO) found in 39.2% and D (OA+PCO) was seen in 29.8% of the patients.
Conclusion: According to the results, there was no significant association between PCOD phenotypes and clomiphene resistance. Finally, A and D phenotypes were frequent types with clomiphene resistance.

Highlights

 According to the results, there was no significant association between PCOD phenotypes and clomiphene resistance. Finally, A and D phenotypes were frequent types with clomiphene resistance.

Keywords

Main Subjects

1. Frank S. Polycystic ovary syndrome. N Engl J Med. 1995;333:853-61. [DOI:10.1056/NEJM199509283331307] [PMID]
2. Azziz R, Woods KS, Reyna R, Key TJ, Kenochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary in an unselected population. J Clin Endocrinol Metab. 2004;89:2745-9. [DOI:10.1210/jc.2003-032046] [PMID]
3. Rotterdam ESHRE-ASRM sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Human Reprod. 2004;19:41-7. [DOI:10.1093/humrep/deh098] [PMID]
4. Shahbazian HB, Shahbazian N, Haghighi M, Khodadadi M. Prevalence of metabolic syndrome in patients with poly cystic ovary syndrome in Ahwaz. Jundishapur Sci Med J; 2011;10(6):595-604.
5. Balen A. The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol. 2004;18(5):685-706. [DOI:10.1016/j.bpobgyn.2004.05.004] [PMID]
6. Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119-29. [DOI:10.1056/NEJMoa1313517] [PMID] [PMCID]
7. Hajishafiha M, Dehghan M, Kiarang N, Sadegh-Asadi N, Shayegh SN, Ghasemi-Rad M. Combined letrozole and clomiphene versus letrozole and clomiphene alone in infertile patients with polycystic ovary syndrome. Drug Des Devel Ther. 2013;7:1427-31. [DOI:10.2147/DDDT.S50972] [PMID] [PMCID]
8. Roy KK, Baruah J, Singla S, Sharma JB, Singh N, Jain SK, et al. A prospective randomized trial comparing the efficacy of Letrozole and Clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. J Hum Reprod Sci. 2012;5(1):20-5. [DOI:10.4103/0974-1208.97789] [PMID] [PMCID]
9. Abdali F, Taghavi S, Vazifekhah S, Naghavi Behzad M, Mirza Aghazadeh Attari M. Effect of Progesterone on Latent Phase Prolongation in Patients With Preterm Premature Rupture of Membranes. Acta Med Iran. 2017; 55(12):772-8.
10. Saha L, Kaur S, Saha PK. N-acetyl cysteine in clomiphene citrate resistant polycystic ovary syndrome: A review of reported outcomes. J Pharmacol Pharmacother. 2013;4(3):187-91. [DOI:10.4103/0976-500X.114597] [PMID] [PMCID]
11. Brown J, Farquhar C. Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome. Cochrane Database Syst Rev. 2016;15;12:CD002249. [DOI:10.1002/14651858.CD002249.pub5] [PMID] [PMCID]
12. Nasseri S, Ledger WL. Clomiphene citrate in the twenty-first century. Hum Fertil (Camb). 2001;4(3):145-51. [DOI:10.1080/1464727012000199212] [PMID]
13. Dasari P, Pranahita G. The efficacy of metformin and clomiphene citrate combination compared with clomiphene citrate alone for ovulation induction in infertile patients with PCOS. J Hum Reprod Sci. 2009;2(1):18-22. [DOI:10.4103/0974-1208.51337] [PMID] [PMCID]
14. Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril. 2005;83(6):1717-30. [DOI:10.1016/j.fertnstert.2005.01.096] [PMID]
15. Carmina E, Azziz R. Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. Fertil Steril. 2006;86 Suppl 1:S7-8. [DOI:10.1016/j.fertnstert.2006.03.012] [PMID]
16. Seyedoshohadaei F, Zandvakily F, Shahgeibi S. Comparison of the effectiveness of clomiphene citrate, tamoxifen and letrozole in ovulation induction in infertility due to isolated unovulation. Iran J Reprod Med. 2012;10(6):531-6.
17. Ramezanali F, Ashrafi M, Hemat M, Arabipoor A, Jalali S, Moini A. Assisted reproductive outcomes in women with different polycystic ovary syndrome phenotypes: the predictive value of anti-Müllerian hormone. Reprod Biomed Online. 2016;32(5):503-12. [DOI:10.1016/j.rbmo.2016.01.010] [PMID]
18. Ciftci CF, Uckuyu A, Karadeli E, Turhan E, Toprak E, Ozcimen EE. Phenotypic subgroups of polycystic ovary syndrome have different intra-renal resistance symptoms. Ginekol Pol. 2012;83(12):910-5.
19. Pehlivanov B, Orbetzova M. Characteristics of different phenotypes of polycystic ovary syndrome in a Bulgarian population. Gynecol Endocrinol. 2007;23(10):604-9. [DOI:10.1080/09513590701536246] [PMID]
20. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998; 338(26):1876-80. [DOI:10.1056/NEJM199806253382603] [PMID]
21. Rouzi AA, Ardawi MS. A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril. 2006;85(2):428-35. [DOI:10.1016/j.fertnstert.2005.07.1312] [PMID]
22. Palomba S, Pasquali R, Orio Jr F, Nestler JE. Clomiphene citrate, metformin or both as first‐step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head‐to‐head randomized controlled studies and meta‐analysis. Clin Endocrinol. 2009;70(2):311-21. [DOI:10.1111/j.1365-2265.2008.03369.x] [PMID]
23. Ellakwa HE, Sanad ZF, Hamza HA, Emara MA, Elsayed MA. Predictors of patient responses to ovulation induction with clomiphene citrate in patients with polycystic ovary syndrome experiencing infertility. Int J Gynaecol Obstet. 2016;133(1):59-63. [DOI:10.1016/j.ijgo.2015.09.008] [PMID]
24. Abu Hashim H, Foda O, Ghayaty E. Combined metformin‐clomiphene in clomiphene‐resistant polycystic ovary syndrome: a systematic review and meta‐analysis of randomized controlled trials. Acta Obstet Gynecol Scand. 2015;94(9):921-30. [DOI:10.1111/aogs.12673] [PMID]